0.620
0.03 (4.80%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Channel Therapeutics Corporatio | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 80.76% |
| % Held by Institutions | 7.07% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Dec 2024 | Announcement | Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine |
| 18 Dec 2024 | Announcement | Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model |
| 21 Nov 2024 | Announcement | Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates |
| 29 Oct 2024 | Announcement | Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain |
| 28 Oct 2024 | Announcement | Chromocell to Present at Upcoming Fall Investor Conferences |
| 24 Oct 2024 | Announcement | Chromocell Announces Amendment to Stock Repurchase Plan |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |